Abstract
PURPOSE: The relationship between caveolin-1 (CAV1) G14713A polymorphism and cancer susceptibility remains inconclusive. The current meta-analysis was performed on the basis of a systematic search in electronic databases for a more precise estimation of the associations. METHODS: Odds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect. RESULTS: A total of 12 studies including 4,994 cases and 5,606 controls were involved in this meta-analysis. In the overall analysis, CAV1 G14713A polymorphism was significantly associated with an increased risk of cancer (A vs G: OR =1.77, 95% CI: 1.49-2.10, P het<0.01; [AA + AG] vs GG: OR =2.03, 95% CI: 1.64-2.53, P het<0.01; AA vs [AG + GG]: OR =1.72, 95% CI: 1.40-2.12, P het<0.01; AA vs GG: OR =2.24, 95% CI: 1.69-2.98, P het<0.01; AG vs GG: OR =1.98, 95% CI: 1.62-2.41, P het<0.01). Subgroup analysis by cancer type showed that CAV1 G14713A polymorphism was associated with an increased risk of digestive system cancer and other cancer types. CONCLUSION: Our findings suggest that CAV1 G14713A polymorphisms may modify the risk of cancer, especially digestive system cancer. However, further well-designed studies are warranted to validate this association.